C
ClearPoint Neuro, Inc. (CLPT)
NCM – Real vaqt narxi. Valyuta: USD
12.64
+0.33 (2.68%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
12.64
+0.33 (2.68%)
Yopilishda: May 12, 2026, 4:00 PM EDT
ClearPoint Neuro, Inc., tijorat bosqichidagi tibbiy asboblar ishlab chiqaruvchi kompaniya, AQShda miyadagi minimal invaziv jarrohlik muolajalarini o'tkazish uchun platformalarni ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya ClearPoint tizimlarini taklif etadi, jumladan ClearPoint apparat ta'minoti, boshni fiksatsiya qiluvchi ramka, kompyuter ish stantsiyasi va xonadagi monitorni o'z ichiga oladi; va ClearPoint bir martalik buyumlari, jumladan SmartFrame traektoriyasi qurilmasi, qo'lda boshqarish moslamasi va tegishli aksessuarlar, hamda uning SmartFlow Neuro kanyulasi. Shuningdek, u jarrohlik rejalashtirish, qurilmani tekislash, maqsadga yo'naltirish va muolajani monitoring qilishda shifokorga yordam beradigan ClearPoint dasturiy ta'minotini; yumshoq to'qimalarni nekroz qilish yoki koagulyatsiya qilish uchun ClearPoint Prism Neuro lazer terapiyasi tizimini; va faol suyuqlik almashinuv platformasi bo'lgan IRRAflow tizimini taqdim etadi. Bundan tashqari, kompaniya o'zining farmatsevtika va boshqa tibbiy texnologiyalar bo'yicha hamkorlariga laboratoriya sinovlari, preklinik tadqiqotlar, klinik sinovlarni qo'llab-quvvatlash, tartibga solish bo'yicha maslahatlar va preklinikadan klinik muhitga o'tkazish kabi maslahat xizmatlarini taklif etadi. U Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, Kaliforniya universiteti, San-Fransisko va NE Scientific, LLC bilan litsenziyalash va hamkorlik shartnomalariga ega. Kompaniya ilgari MRI Interventions, Inc. nomi bilan tanilgan va 2020 yil fevral oyida ClearPoint Neuro, Inc. nomini olgan. ClearPoint Neuro, Inc. 1998 yilda ro'yxatga olingan va Solana Beach, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Paul S. Larson FAANS, M.D. | Chief Medical Officer |
| Mr. Danilo D'Alessandro | Chief Financial Officer |
| Mr. Jeremy L. Stigall | Chief Business Officer |
| Mr. Joseph Michael Burnett | President, CEO & Director |
| Mr. Mazin Sabra | Chief Operating Officer |
| Mr. Robert C. Korn | Senior Vice President of Sales & Business Development |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-23 | DEFA14A | clpt-20260423.htm |
| 2026-04-10 | DEF 14A | clpt-20260410.htm |
| 2026-03-17 | 10-K | clpt-20251231.htm |
| 2026-02-09 | S-8 | clpt-20260209.htm |
| 2026-02-05 | D | |
| 2026-02-05 | 8-K/A | clpt-20251120.htm |
| 2026-01-14 | S-3 | clearpoint_s3.htm |
| 2026-01-12 | 8-K | clpt-20260112.htm |
| 2026-01-05 | 8-K | clpt-20260105.htm |
| 2025-11-20 | 8-K | clpt-20251120.htm |
| Ms. Ellisa Cholapranee J.D. | General Counsel & Secretary |
| Ms. Mary McNamara-Cullinane RAC | Senior Vice President of Regulatory Affairs |
| Ms. Megan Faulkenberry | Senior Vice President of Quality |